Stories from people navigating neuroendocrine tumors — diagnosis, treatment, caregiving, and the ordinary days in between.
2 stories
Conference Coverage
Alpha and beta emitters bring distinct dosimetry, manufacturing and safety challenges. A conference review highlights why their development cannot be judged as a cross-cancer efficacy contest.
Dr. Abu Bakar · November 2, 2026 · 7 min
Oncology
In a phase 3 head-to-head trial, [177Lu]Lu-edotreotide extended progression-free survival compared with everolimus in progressive, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Rayan Salih · 6 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.